Stimulation of tPA-dependent provisional extracellular fibrin matrix degradation by human recombinant soluble melanotransferrin.

Tissue-type plasminogen activator (tPA) and its substrate plasminogen (Plg) are key components in the fibrinolytic system. We have recently demonstrated, that truncated human recombinant soluble melanotransferrin (sMTf) could stimulate the activation of Plg by urokinase plasminogen activator and inhibit angiogenesis. Since various angiogenesis inhibitors were shown to stimulate tPA-mediated plasminogen activation, we examined the effects of sMTf on tPA-dependent fibrinolysis. This study demonstrated that sMTf enhanced tPA-activation of Plg by 6-fold. sMTf also increased the release of [125I]-fibrin fragments by tPA-activated plasmin. Moreover, we observed that the interaction of sMTf with Plg provoked a change in the fibrin clot structure by cleaving the fibrin alpha and beta chains. Overall, the present study shows that sMTf modulates tPA-dependent fibrinolysis by modifying the clot structure. These results also suggest that sMTf properties could involve enhanced dissolution of the provisional extracellular fibrin matrix.

[1]  D. Richardson,et al.  The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain. , 2004, Biochimica et biophysica acta.

[2]  J. Brown,et al.  Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.

[4]  D. Richardson,et al.  Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human. , 2005, Biochimica et biophysica acta.

[5]  R. Béliveau,et al.  Regulation of plasminogen activation: a role for melanotransferrin (p97) in cell migration. , 2003, Blood.

[6]  R. Doolittle,et al.  Human melanoma-associated antigen p97 is structurally and functionally related to transferrin , 1982, Nature.

[7]  D. Rijken,et al.  Basic principles in thrombolysis: regulatory role of plasminogen. , 2001, Thrombosis research.

[8]  Michel Demeule,et al.  The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity , 2004, Investigational New Drugs.

[9]  L. Lorand.  Factor XIII: Structure, Activation, and Interactions with Fibrinogen and Fibrin , 2001, Annals of the New York Academy of Sciences.

[10]  A. Sahni,et al.  Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires αvβ3 , 2004 .

[11]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[12]  E. Voest,et al.  Do antiangiogenic protein fragments have amyloid properties? , 2004, Blood.

[13]  W. Jefferies,et al.  Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein. , 1994, The Journal of biological chemistry.

[14]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Soria,et al.  Effects of Abciximab on the Architecture of Platelet-Rich Clots in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention , 2001, Circulation.

[16]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[17]  A. Sahni,et al.  Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. , 2004, Blood.

[18]  R. Béliveau,et al.  Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system. , 2005, Biochimica et biophysica acta.

[19]  Serge Gauthier,et al.  Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease. , 2003, The Biochemical journal.

[20]  R. Béliveau,et al.  Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: a key phenomenon for cell invasion. , 2005, Experimental Cell Research.

[21]  H. Feldman,et al.  Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease , 1996, Nature Medicine.

[22]  C. Francis,et al.  Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights. , 1983, Biochimica et biophysica acta.

[23]  J. Soria,et al.  Thrombotic dysfibrinogenemia. Fibrinogen "Caracas V" relation between very tight fibrin network and defective clot degradability. , 2000, Thrombosis research.

[24]  J. Jesty,et al.  Vascular endothelial groth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatininase a activation and cell proliferation , 1998, International journal of cancer.

[25]  E. Voest,et al.  No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. , 2000, European journal of cancer.

[26]  D. Collen,et al.  Molecular Basis of Fibrinolysis, as Relevant for Thrombolytic Therapy , 1995, Thrombosis and Haemostasis.

[27]  D. Jackson,et al.  Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. , 2002, Cancer research.

[28]  D. O'Shannessy,et al.  Immobilization chemistries suitable for use in the BIAcore surface plasmon resonance detector. , 1992, Analytical biochemistry.

[29]  O. Gotoh,et al.  Membrane-bound transferrin-like protein (MTf): structure, evolution and selective expression during chondrogenic differentiation of mouse embryonic cells. , 1999, Biochimica et biophysica acta.

[30]  S. Sherry,et al.  The preparation and properties of human fibrinogen of relatively high solubility. , 1966, Biochemistry.

[31]  C. Hack,et al.  Interleukin 12 induces activation of fibrinolysis and coagulation in humans , 2001, British journal of haematology.

[32]  G. Tsurupa,et al.  Conformational Changes upon Conversion of Fibrinogen into Fibrin , 2001, Annals of the New York Academy of Sciences.

[33]  A. Blinc,et al.  Atomic force microscopy of fibrin networks and plasma clots during fibrinolysis , 2000 .

[34]  W. Jefferies,et al.  Deletion of the GPI pre-anchor sequence in human p97--a general approach for generating the soluble form of GPI-linked proteins. , 2004, Protein expression and purification.

[35]  Michel Demeule,et al.  High transcytosis of melanotransferrin (P97) across the blood–brain barrier , 2002, Journal of neurochemistry.